Evans T G, Bonnez W, Soucier H R, Fitzgerald T, Gibbons D C, Reichman R C
Infectious Diseases Unit, University of Rochester, NY, USA.
Antiviral Res. 1998 Oct;39(3):163-73. doi: 10.1016/s0166-3542(98)00035-7.
Highly active antiretroviral therapy (HAART) can produce marked increases in peripheral blood CD4+ T cells and decreases in HIV plasma RNA copy numbers. However, it is not clear whether these absolute changes will be accompanied by a recovery in the known naive CD4+ T cell depletion or a decrease in the marked CD8+ T cell activation.
Twenty-nine patients were enrolled in studies of either nucleoside therapy alone or nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir). One hundred and ninety-one examinations were carried out at three baseline time points and during 40 weeks of follow-up to evaluate the effect of HAART on CD4+ memory/naive phenotype and CD8+ T cell activation.
CD4+ and CD8+ T cell number, CD62L/CD45RA expression on CD4+ T cells and CD38 expression on CD8+ T cells were measured by three-color flow cytometry.
Most protease inhibitor treated patients had a significant rise in CD4+ numbers. The marked rise in the CD4+ T cells seen in individuals in this study was not accompanied over a 40-week period by a change in the abnormally low CD4+ naive compartment, and thus was almost completely of memory phenotype. The CD38 expression on CD8+ cells fell during treatment, and decreased to a greater degree than the comparable rise in CD4+ T cell counts. This decrease continued in many patients after the CD4+ T cell rise or viral load decline had plateaued.
HAART results in changes in activation to a greater extent than absolute changes in CD4+ T cell numbers, but is not accompanied by an increase in naive CD4+ T cells. Measurements of CD4+ T cell numbers alone may not allow appropriate interpretation of immune activation or immune competence in patients receiving those drugs.
高效抗逆转录病毒疗法(HAART)可使外周血CD4+ T细胞显著增加,同时使HIV血浆RNA拷贝数降低。然而,尚不清楚这些绝对变化是否会伴随着已知幼稚CD4+ T细胞耗竭的恢复或显著的CD8+ T细胞活化的降低。
29名患者参与了单独核苷治疗或核苷治疗联合蛋白酶抑制剂(齐多夫定+拉米夫定+茚地那韦)的研究。在三个基线时间点以及40周的随访期间进行了191次检测,以评估HAART对CD4+记忆/幼稚表型和CD8+ T细胞活化的影响。
采用三色流式细胞术检测CD4+和CD8+ T细胞数量、CD4+ T细胞上CD62L/CD45RA的表达以及CD8+ T细胞上CD38的表达。
大多数接受蛋白酶抑制剂治疗的患者CD4+数量显著增加。在本研究中,个体中观察到的CD4+ T细胞显著增加在40周内并未伴随着异常低的CD4+幼稚亚群的变化,因此几乎完全是记忆表型。CD8+细胞上的CD38表达在治疗期间下降,且下降程度大于CD4+ T细胞计数的相应增加。在许多患者中,CD4+ T细胞升高或病毒载量下降达到平台期后,这种下降仍在继续。
HAART导致的活化变化程度大于CD4+ T细胞数量的绝对变化,但并未伴随着幼稚CD4+ T细胞的增加。仅测量CD4+ T细胞数量可能无法对接受这些药物治疗的患者的免疫活化或免疫能力进行恰当解读。